Cg Oncology, INC

CG Oncology, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

CG Oncology announced the separation of its President & Chief Operating Officer, Ambaw Bellete, effective June 30, 2026, and the appointment of Arthur Kuan as President.

CG Oncology announced its first quarter 2026 financial results, highlighting progress towards a BLA submission for its lead candidate and a strong cash position sufficient through 2029.

CG Oncology, Inc. announced the appointment of Jim DeTore as its new Chief Financial Officer, effective April 13, 2026, with a compensation package including salary, bonus, stock options, and performance stock units.

CG Oncology, Inc. announced its financial results for the year and fourth quarter ended December 31, 2025, alongside significant progress in its bladder cancer clinical programs and a strong cash position.

CG Oncology, Inc. increased its at-the-market equity offering program by an additional $300 million, bringing the total potential raise to $550 million.

CG Oncology reports Q1 2026 financial results, highlighting a strong cash position of $1.08 billion and continued clinical progress for its lead bladder cancer candidate.

CG Oncology announced positive 24-month Phase 3 clinical trial results for cretostimogene in bladder cancer and acquired Biovire to enhance manufacturing capabilities, despite increased net losses.

CG Oncology reported increased R&D expenses and net losses in Q2 2025, but highlighted significant clinical progress for cretostimogene and a major legal win against ANI Pharmaceuticals.

CG Oncology's Q1 2025 results show increased R&D spending and a net loss, but the company is progressing with clinical trials and anticipates a BLA submission in the second half of 2025.

CG Oncology's third quarter 2024 results show increased spending on research and development, offset by gains from interest income, following a successful IPO.

CG Oncology's second quarter 2024 results show increased spending on research and development following their recent IPO, with a net loss of $18.9 million.

CG Oncology, Inc. reports promising Phase 3 clinical trial data for its lead product candidate, cretostimogene, in high-risk NMIBC, initiating BLA submission and expanding its bladder cancer pipeline.

CG Oncology's 10-K filing highlights positive clinical trial results for cretostimogene, positioning the company for a potential BLA submission in the second half of 2025.

CG Oncology, a late-stage clinical biopharmaceutical company, is advancing its bladder cancer therapeutic, cretostimogene, with promising interim Phase 3 trial results and plans for expanded clinical trials.

Leonard E Post, a Director of CG Oncology, Inc., sold 1,000 shares of common stock on July 15, 2026 for $71.17 per share.

James Mulay, a Director of CG Oncology, Inc., sold 24,165 shares of common stock on July 10, 2026 for $75.16 per share.

CG Oncology, Inc. reports a significant acquisition of common stock by Director Brian Guan-Chyun Liu.

CG Oncology Director Leonard E. Post has sold 5,000 shares of common stock, valued at approximately $350,000, under a pre-arranged Rule 10b5-1 trading plan.

Director James Mulay exercised stock options and sold the resulting shares of CG Oncology, Inc. under a 10b5-1 plan.

Director Victor Edward Tong Jr. was granted 9,354 stock options in CG Oncology, Inc. as part of a standard equity incentive.

CG Oncology, Inc. has filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders to be held on June 4, 2026.

CG Oncology has filed its definitive proxy statement, signaling preparations for an upcoming shareholder meeting.

CG Oncology announces its 2025 Annual Meeting of Stockholders to be held virtually on June 5, 2025, featuring proposals for director elections and ratification of the company's independent auditor.

CG Oncology has filed an amendment to its S-1 registration statement, primarily to include exhibits related to the underwriting agreement and legal opinion, as it prepares for its public offering.

CG Oncology is seeking to raise capital through a secondary stock offering to advance its bladder cancer treatment, cretostimogene, through clinical trials and towards potential commercialization.

CG Oncology seeks to increase its IPO share offering by 3.45 million shares, including an underwriter option, representing no more than 20% of the initial offering price.

CG Oncology is seeking to raise $289 million through an initial public offering to fund the development and commercialization of its bladder cancer therapeutic, cretostimogene.

CG Oncology, a late-stage biopharmaceutical company, is set to launch its IPO on the Nasdaq, aiming to raise capital for its bladder cancer therapeutic, cretostimogene.

Seven Fleet Master Fund LP and related entities filed an amended Schedule 13D for CG Oncology, Inc., detailing an internal ownership restructuring and correcting prior reporting.

Longitude Capital and its affiliates, including Patrick G. Enright and Juliet Tammenoms Bakker, have increased their beneficial ownership in CG Oncology, Inc. to 6.0%, triggering a Schedule 13D filing.

Seven Fleet Partners LP, Seven Fleet Advisors LLC, and Dr. Brian Liu have collectively reported a 1.9% beneficial ownership stake in CG Oncology, Inc., citing an attractive investment opportunity.

T. Rowe Price Investment Management, Inc. has reported beneficial ownership of 8.0% of CG Oncology Inc.'s common stock as of March 31, 2026.

RTW Investments, LP and Roderick Wong have reported a beneficial ownership of 8.3% in CG Oncology, Inc., holding 6,984,808 shares.

The Vanguard Group has filed an amended Schedule 13G, reporting a 0% beneficial ownership in CG Oncology Inc. following an internal realignment.

Wellington Management Group LLP and its affiliates have reported a 7.2% beneficial ownership stake in CG Oncology, Inc. as of September 30, 2025.

The Vanguard Group has reported an increased beneficial ownership of 8.62% in CG Oncology Inc.'s common stock, totaling 6,577,281 shares.

FMR LLC and Abigail P. Johnson have reported a 5.1% beneficial ownership stake in CG Oncology Inc. as of June 30, 2025.